A Pilot study to evaluate the Efficacy and Safety of GFT505 (30 mg) orally administered for 28 days in patients with Frederickson Type IIb Dyslipidemia (Mixed Hyperlipidemia). A double blind, placebo-controlled and randomized study.
Phase of Trial: Phase II
Latest Information Update: 03 Jul 2012
At a glance
- Drugs Elafibranor (Primary)
- Indications Hyperlipoproteinaemia type II; Hyperlipoproteinaemia type IIb
- Focus Therapeutic Use
- Sponsors Genfit
- 03 Jul 2012 Trial location (France) identified, planned patient number 30 added as reported by EudarCT.
- 03 Jul 2012 Official title amended as reported by EudraCT.
- 09 Oct 2007 New trial record.